Thursday, 5 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 11, 2026

‘I had hoped to be retired’: 66-year-old still works 11-hour days with zero savings. Here’s how you can avoid this fate

View original at finance.yahoo.com
‘I had hoped to be retired’: 66-year-old still works 11-hour days with zero savings. Here’s how you can avoid this fate Photo: CBS News Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • She works 11-hour days across two jobs with no savings, 401(k), or emergency fund

    80% confidence
  • Only 43% of American adults could handle an unexpected $1,000 expense with their savings

    80% confidence
  • Employment rate for Americans 65+ has nearly doubled compared to 35 years ago

    80% confidence
  • She had hoped to be retired, playing piano and enjoying life

    80% confidence
  • Financial situation has been life-threatening

    80% confidence
  • Approximately one in five Americans aged 65 and over were employed in 2023

    80% confidence
  • Moby's stock recommendations have beaten the S&P 500 by almost 12% on average over four years across almost 400 stock picks

    80% confidence
  • 47% of men aged 55 to 66 have no personal retirement savings

    80% confidence
  • Nearly half of U.S. women aged 55 to 66 have no personal retirement savings

    80% confidence
  • Recommends saving enough to cover three to six months of living expenses for emergencies

    80% confidence
  • Gold could climb to $6,200 per ounce by the end of 2026

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com